EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Norcantharidin inhibits TOP2A expression via H3K27me3 mediated epigenetic regulation to alleviate the progression of hepatocellular carcinoma

Ruibing Wu, Hengye Yuan, Yuehua Wang, Xianggang Gou, Wanhua Hou, Zhongzheng Zhou, Xinran Wang, Xiuling Deng, Changshan Wang, Haisheng Wang, Jia Yan

Frontiers in Pharmacology · 03.04.2025 · 16

DOI: 10.3389/fphar.2025.1541298 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 03.04.2025. Verfasst von Ruibing Wu und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medicine, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Norcantharidin (NCTD), a bioactive compound derived from traditional Chinese medicine, has demonstrated promising anticancer activity against multiple malignancies, particularly hepatocellular carcinoma (HCC). However, its epigenetic regulatory mechanisms and associated transcriptional consequences remain poorly characterized.

Methods

In this study, we integrated biochemical assays with a panel of cellular analyses assessing cell viability, proliferation, colony formation, and migratory capacity to investigate NCTD’s therapeutic potential in HCC progression. Potential molecular targets of NCTD were systematically identified through integrated network pharmacology approaches. Chromatin immunoprecipitation quantitative PCR (ChIP-qPCR) was performed to quantify H3K27me3 enrichment level at the TOP2A locus in NCTD-treated HCC cells. Molecular docking simulations were employed to examine structural interactions between NCTD and EZH2 (enhancer of zeste homolog 2), while co-immunoprecipitation assays were further conducted to validate protein-protein interactions between EZH2 and protein phosphatase 1 (PP1).

Results

We identified topoisomerase IIα (TOP2A) as a critical molecular target mediating NCTD’s anti-HCC effects. Functional characterization revealed that NCTD significantly attenuated HCC cell proliferation and induced G2/M phase cell cycle arrest through disruption of the TOP2A-p53 signaling axis. Mechanistic investigations demonstrated that NCTD epigenetically suppresses TOP2A transcription via PRC2 (Polycomb Repressive Complex 2)-mediated deposition of the repressive histone mark H3K27me3 at the TOP2A promoter. Structural biology analyses confirmed direct binding of NCTD to EZH2 protein, consequently impairing PP1-mediated dephosphorylation and enhancing PRC2 complex stability.

Conclusion

Our findings establish that NCTD exerts anticancer effects in HCC through epigenetic silencing of TOP2A. This work not only elucidates a novel pharmacoepigenetic mechanism underlying NCTD’s antitumor activity but also provides translational rationale for developing PRC2-targeted therapeutic strategies in HCC management.

Schlagwörter

Stichwörter der Autor:innen

EZH2H3K27me3HCCNCTDTOP2A

Autor:innen und Institutionen

  • School of Basic Medicine, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China.
  • College of Life Science, Inner Mongolia University, Hohhot, Inner Mongolia, China.
  • Medical Experimental Center of Basic Medical School, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China.

Zitieren

APA

Wu, R., Yuan, H., Wang, Y., Gou, X., Hou, W., Zhou, Z., Wang, X., Deng, X., Wang, C., Wang, H., & Yan, J. (2025). Norcantharidin inhibits TOP2A expression via H3K27me3 mediated epigenetic regulation to alleviate the progression of hepatocellular carcinoma. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1541298

Vancouver

Wu R, Yuan H, Wang Y, Gou X, Hou W, Zhou Z, et al. Norcantharidin inhibits TOP2A expression via H3K27me3 mediated epigenetic regulation to alleviate the progression of hepatocellular carcinoma. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1541298

BibTeX
@article{Wu2025,
  author = {Wu, Ruibing and Yuan, Hengye and Wang, Yuehua and Gou, Xianggang and Hou, Wanhua and Zhou, Zhongzheng and Wang, Xinran and Deng, Xiuling and Wang, Changshan and Wang, Haisheng and Yan, Jia},
  title = {Norcantharidin inhibits TOP2A expression via H3K27me3 mediated epigenetic regulation to alleviate the progression of hepatocellular carcinoma},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1541298}
}
Kostenlos starten →